O-016 Outcomes after endovascular mechanical thrombectomy for low national institutes of health stroke scale (NIHSS): a multicenter study

ConclusionsMT is an effective and safe treatment for appropriately selected ischemic stroke patients presenting with low NIHSS. Diabetes and prior stroke are predictors of functional dependence at 90 days, and prior stroke is also associated with mortality, suggesting that MT should be offered judiciously to patients with these risk factors. Our findings signal the need for a randomized trial comparing MT versus medical management for LVO patients with low NIHSS.Disclosures I. Abecassis: 2; C; IschemaView (Rapid), Remedy Robotics. E. Almallouhi: None. R. Chalhoub: None. S. Kassab: None. E. Bass: None. D. Ding: None. I. Maier: None. M. Psychogios: None. J. Liman: None. A. Alawieh: None. S. Wolfe: None. A. Arthur: 1; C; Balt, Medtronic, Microvention, Penumbra, Siemens. 2; C; Balt, Johnson and Johnson, Microvention, Medtronic, Penumbra, Scientia, Siemens, Stryker. 4; C; Azimuth, Bendit, Cerebrotech, Endostream, Magneto, Mentice, Neurogami, Serenity, Synchron, Triad medical, Vastrax, VizAI. P. Kan: None. J. Kim: None. R. De Leacy: 1; C; Hypervenetion, Siemens. 2; C; Stryker, Medical Metrics, Proxima, Cerenovus, Asahi Intec, Imperative Care. 4; C; Spartan Micro, Vastrax, QApel, Synchron, Endostream. J. Osbun: 2; C; Medtronic, Terumo, Microvention, In Neuro Co. P. Jabbour: None. J. Grossbereg: 1; C; Georgia Research Alliance, Emory Medical Care Foundation, Emory Neurosurgery Catalyst. 2; C; Cognition. M. Park: None. J. Mascitelli: 2; C; Stryker. M. Levitt: None. A. Polifka: None. S...
Source: Journal of NeuroInterventional Surgery - Category: Neurosurgery Authors: Tags: SNIS 19th annual meeting oral abstracts Source Type: research